 PARIS and CAMBRIDGE, Mass., April 13, 2021 GLOBE NEWSWIRE -- BIOPHYTIS SA NasdaqCM: BPTS, Euronext Growth Paris: ALBPS, a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, has been made aware of a false report regarding the status of its COVA study of its Sarconeos BIO101 treatment in COVID-19 in Brazil. On April 12, 2021, an article was released via WBOC unbeknownst to BIOPHYTIS. The press release was misleading and released without BIOPHYTIS knowledge by unknown sources. 